Acasti Announces Third Quarter Results LAVAL, Quebec, Jan.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Acasti Announces Third Quarter Results

LAVAL, Quebec, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti " or the " Corporation ") (Nasdaq: ACST ) (TSX-V: APO ), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its results for the three and nine-months ended November 30, 2014.

The Corporation has made important progress in its drug development program to obtain regulatory approval to distribute and market CaPre® as a prescription drug. Full data for Acasti's Pharmacokinetic (PK) trial was received in December 2014 and a complete set of data for the Phase II TRIFECTA trial is now expected by the end of February 2015.

In expectation of full TRIFECTA results being available soon, Acasti has contacted the US Food and Drug Administration (FDA) and requested a meeting to discuss next steps in the clinical development of CaPre®. The meeting is expected to take place in Acasti's first quarter ending May 31, 2015. Following the FDA meeting, Acasti expects to have a clearer picture on the projected timeline for its Phase III clinical trial.

"In preparation for Phase III clinical testing, Acasti is ramping up Good Manufacturing Practices (GMP) production of CaPre® to ensure sufficient supplies are available," highlighted Pierre Lemieux, PhD, Acasti's Chief Operating Officer.

Third Quarter Financial Results

  • Revenues were $29,000 for the third quarter ended November 30, 2014, versus $28,000 for the quarter ended November 30, 2013
  • Research and development (R&D) expenses were $1,749,000 for the quarter, versus $1,279,000 in the prior year
  • Adjusted EBITDA was negative $(2,099,000) for the quarter, versus negative $(1,574,000) in the prior year
  • Net earnings were $3,012,000 for the quarter, versus a net loss of $(3,856,000) in the prior year.

Sales continue to be generated from the commercialization of Onemia®, the Corporation's medical food product. Acasti relies on a limited number of distributors and clients and therefore revenues may vary significantly from quarter to quarter.

The year-over-year decrease in adjusted EBITDA was largely due to an increase in R&D expenses, resulting from higher professional fees and contract expenses related to Acasti's clinical trials.

The $3.0 million of net earnings recorded for the current quarter is largely due to a decrease in the fair value of Acasti's derivative warrant liability arising from its 2013 public offering. The warrants are derivative liabilities, for accounting purposes, due to the currency of the exercise price (US dollars) being different from Acasti's functional currency (Canadian dollars). The derivative warrant liabilities are required to be measured at fair value at each reporting date with changes in fair value recognized in earnings. The Corporation uses the Black-Scholes pricing model to determine fair value.

Year-to-Date Financial Results

  • Revenues were $92,000 for the nine months ended November 30, 2014, versus $301,000 for the corresponding period ended November 30, 2013.
  • Research and development (R&D) expenses were $4,771,000 for the nine-month period, compared to $3,584,000 in the prior year
  • Adjusted EBITDA was negative $(6,244,000) for the current year-to-date, versus negative $(4,607,000) in the prior year
  • Net earnings were $656,000, versus a net loss of $(9,059,000) in the prior year.

The nine-month year-over-year variances are mainly attributable to the same factors highlighted above for the three-months ended November 30, 2014.

NASDAQ Notification Regarding Minimum Bid Requirements

On November 7, 2014 Acasti received notification from the NASDAQ Listing Qualifications Department for failing to maintain a minimum bid price of US$1.00 per share for 30 consecutive business days. This notification has no immediate effect on the listing of Acasti's shares and the Corporation has 180 calendar days, or until May 6, 2015, to regain compliance. Acasti's shares must close at US$1.00 per share or more for a minimum of ten (10) consecutive business days to regain compliance.

If Acasti does not regain compliance within the initial 180-day period, it may be eligible for an additional 180 calendar days to regain compliance. The Corporation is currently evaluating all available options to resolve the deficiency and regain compliance with the Minimum Bid Price Rule.

About Acasti Pharma Inc.

Acasti is an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, also known as dyslipidemia. Because krill feeds on phytoplankton (diatoms and dinoflagellates), it is a major source of phospholipids and polyunsaturated fatty acids ("PUFAs"), mainly eicosapentaenoic acid ("EPA") and docosahexaenoic acid ("DHA"), which are two types of omega-3 fatty acids well known to be beneficial for human health. CaPre®, currently Acasti's only prescription drug candidate, is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to help prevent and treat hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. ONEMIA®, a medical food and currently Acasti's only commercialized product, is a purified omega-3 phospholipid concentrate derived from krill oil with lower levels of phospholipids, EPA and DHA content than CaPre®.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Acasti's latest Annual Information Form, which also forms part of Acasti's latest annual report on Form 20-F, and which is available on SEDAR at www.sedar.com , on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Acasti's website at acastipharma.com (the "AIF"). All forward-looking statements in this press release are made as of the date of this press release. Acasti does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Acasti's public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors".

Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Acasti Contact: Andre Godin Interim President & CEO Interim CFO Acasti +1.450.687.2262 acastipharma.com John Ripplinger Investor Relations +1.450.687.2262 acastipharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 70

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 548

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 53

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 306

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 52

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 458

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 117

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 124

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading

Top 5 Most Recently Viewed Articles

WIC Forum Set to Transform Cultural Heritage through Digitalization

Updated Category News Views 194

WIC Forum Set to Transform Cultural Heritage through Digitalization The World Internet Conference (WIC) recently held a significant press conference to announce the upcoming Cultural Heritage Digitalization Forum. This important event aims to explore the relationship between technology and cultural heritage preservation. Event Overview The WIC's briefing included key...

Continue Reading
Nordea Bank Rectifies Errors in Exchange Traded Products

Updated Category News Views 194

Correction of Errors in Exchange Traded Products Nordea Bank Abp, acting as the issuer, has identified and decided to amend certain final terms related to instruments listed in their documentation. This corrective action is taken based on identified manifest errors that needed rectification. The bank is entitled to make such modifications under subsection (i) of Condition...

Continue Reading
NEXE Innovations 2024 Review: A New Era of Sustainability Ahead

Updated Category News Views 324

Strategic Developments at NEXE Innovations NEXE Innovations Inc. (TSXV: NEXE) is making headlines with its impressive strides toward sustainable growth. This innovative company is dedicated to developing compostable materials to meet the rising demand for eco-friendly solutions. Their focus is on high-performance products that serve various markets, creating robust...

Continue Reading
Analyzing Affiliated Managers Group's Price-to-Earnings Ratio

Updated Category News Views 144

Understanding Affiliated Managers Group's Stock Performance In today's market, Affiliated Managers Group Inc. (NYSE: AMG) is trading at $281.79, reflecting a slight increase of 0.97%. Over the last month, the stock has appreciated by 5.89%, showcasing an impressive 50.30% rise over the past year. Such robust performance invites optimism among long-term investors, although...

Continue Reading
Revolutionizing Medical Device Development Through Live Prototyping

Updated Category News Views 182

Accelerating Medical Device Innovation In the fast-evolving world of healthcare technology, the demand for speed and efficiency has never been more critical. Elevaris Medical Devices, a prominent Contract Development and Manufacturing Organization (CDMO), is at the forefront of this transformation. They specialize in working with multi-national healthcare firms, global...

Continue Reading